U.S. Software Stock News

If you’ve found yourself eyeing Graham Holdings after its most recent moves, you’re not alone. Whether you’re considering holding, trimming, or jumping in fresh, the stock’s behavior lately has gotten plenty of investors talking. Despite facing a pullback of 13.7% over the last 30 days, which might have rattled less seasoned hands, Graham Holdings is still up an impressive 18.1% year to date and 33.8% over the past year. Step back further, and you see gains of 67.4% across three years and...

Ventyx Biosciences recently announced positive topline results from its Phase 2 clinical trial of VTX3232, showing significant reductions in key inflammatory biomarkers such as hsCRP and IL-6 in patients with obesity and cardiovascular risk factors. An interesting insight from the study is that VTX3232 achieved a robust safety and tolerability profile, both as a standalone therapy and in combination with semaglutide, highlighting its potential as a new oral anti-inflammatory option in...

If you’ve been eyeing CECO Environmental and wondering whether it’s time to get in, stay patient, or take wins off the table, you’re not alone. This stock has been quietly (and not so quietly) rewarding attentive investors with some eye-popping returns. Just check out the numbers: up 6.7% over the past week, 5.9% in the last month, and an astonishing 66.1% so far this year. Zoom out further, and the gains are even more impressive: nearly 95% for the past year and a staggering 637% over the...

If you are weighing your next move with Old National Bancorp, you are certainly not alone. Investors are taking note as this regional bank’s stock has delivered a rollercoaster of returns lately. In just the past week, shares have climbed 6.0%, a sharp turnaround from last month’s dip of almost 5%. With a strong 15.4% return over the last year and an impressive 76.6% gain across five years, Old National has shown that its long-term story is anything but boring. What is driving these swings?...

Paul Mueller (MUEL) posted a noteworthy turnaround in its recent earnings, swinging to profitability over the past year after a stretch of losses. Earnings have accelerated at an average annual rate of 41.3% over the last five years, and the company’s net profit margin has expanded as profitability returned. The latest data points to attractive value with shares trading below estimated fair value, but investors should keep an eye on the high proportion of non-cash earnings when weighing the...

If you’re wondering whether to keep holding, buy more, or finally part ways with Genpact, you’re not alone. The stock has been on a bit of a roller coaster, inviting both cautious observers and value hunters to the table. Over the past year, Genpact’s price has ticked up a respectable 4.5%, despite a choppy ride that includes a 6.4% dip over the past month and an overall 8.1% slide year-to-date. While that kind of short-term volatility might spook some investors, it can also mean opportunity,...

If you’re thinking about whether Opera is a buy, sell, or just one to keep on your watchlist, you’re not alone. In the last week, the stock slipped by 3.2%, following a choppier month where it dropped 17.2%. That might make some investors uneasy, but if you zoom out, Opera’s story gets a lot more interesting. Despite the recent turbulence, the stock is still up a massive 356.5% over three years and 116.2% over the last five years. So, what’s driving these swings, and what could that mean for...

Affinity Bancshares (AFBI) reported a net profit margin of 23.7%, up from 18.3% a year ago, underscoring higher profitability relative to revenue. Earnings growth surged 34.5% year over year, materially above the company’s 5-year average of 3.4% per year and further highlighted by management as high quality. With margins improving and consistent profit gains, investors are likely to take note of both the stronger bottom line and the context of higher valuation multiples compared to industry...

Bullish momentum is building around Churchill Capital Corp X (CCCX) as options traders pile into call contracts. Volumes have doubled the norm and implied volatility is spiking. The extremely low Put/Call Ratio suggests that optimism is widespread. See our latest analysis for Churchill Capital Corp X. After a quiet start to the year, Churchill Capital Corp X’s share price has climbed significantly in recent weeks, notching a 51.8% gain over the past month and doubling since the beginning of...

Core Scientific (CORZ) extended its streak of unprofitability this quarter, with net losses having grown at an average rate of 23.1% per year over the past five years. Looking ahead, analysts forecast an 83.98% annual growth in earnings and expect the company to achieve profitability within three years, while revenue is projected to expand at 36.3% per year, well above the US market average. Despite these optimistic growth projections, Core Scientific’s net profit margin has yet to show...

Caledonia Mining Corporation Plc recently reported gold production of 19,106 ounces for the third quarter of 2025 and reiterated its increased 2025 annual production guidance of 75,500 to 79,500 ounces. This consistent operational performance and reaffirmed outlook highlight management’s confidence in delivering stable gold output despite previous periods of investor scrutiny. We'll explore how the company's reaffirmed 2025 gold production guidance could shape Caledonia Mining's investment...

Thinking about what’s next for Motorola Solutions stock? You’re not alone. With shares recently closing at $438.98, investors are trying to determine whether it’s time to double down or take some gains off the table. Over the past year, the stock has drifted lower, down 4.1%, and it has shed 4.4% year-to-date. Even the shorter-term moves have been a bit uninspiring, with a 3.8% slip in the last month and a 1.4% dip over the past week. However, not everything is as quiet as it seems. Zoom out...

If you are puzzling over what to make of Solventum's stock right now, you are in good company. Over the past month, shares have barely budged, up just 0.1%, even as the overall market has moved with more conviction. That kind of flat performance can frustrate momentum seekers, but for the valuation-conscious, it might hint at opportunity or a story that is still developing. Digging a bit into the recent price action, Solventum is up a healthy 8.4% so far this year, quickly bouncing back from...

World Kinect (NYSE:WKC) remains unprofitable, with losses deepening at an average rate of 45.7% per year over the last five years and no improvement in its net profit margin this year. Revenue is forecast to edge down slightly by 0.01% per year in the near term, but the major storyline is an expected earnings turnaround. Analysts see profits growing by 125.91% per year, with the company potentially returning to profitability within three years, an outlook that stands out in the sector. See...

Trying to figure out what to do with CSX stock right now? You're not alone. After another month of strong gains, with shares up 6.2% over the last 30 days and a year-to-date return at a solid 12.3%, investors are wondering if the growth train has enough steam left or if it’s time to lock in some profits. Despite a slight dip of 1.3% this past week, CSX has delivered a healthy 46.7% total return over the past five years. This performance puts it ahead of many peers in the transportation...

First Capital (FCAP) posted net profit margins of 31.2%, an improvement over last year’s 28.7%. Earnings growth surged by 25.1%, which is well above the company’s five-year average of 4.9% per year. Shares are trading at $42.92, below the estimated fair value of $72.33. This suggests potential for upside as investors take note of the company’s high-quality and accelerating earnings profile. See our full analysis for First Capital. Next, we’ll see how these latest numbers compare to the...

Gorman-Rupp (GRC) posted a notable 31.8% earnings growth over the past year, outpacing its own five-year average of 14.8% per year. Net profit margins advanced to 7.4% from last year's 5.8%, while forecasts call for a 13.44% annual earnings growth, just under the broader US market’s 15.5%. On the valuation side, the company’s price-to-earnings ratio of 24.4x stands below both its peer group average of 45.4x and the US Machinery industry benchmark of 24.6x. Shares are trading a touch above the...

Univest Financial (UVSP) has posted a net profit margin of 28.1%, up from 25.4% a year ago, and reported profit growth of 18.7% over the past year, well above its five-year average annual earnings growth rate of 2.5%. The company’s outlook includes forecast annual earnings growth of 2.1% and revenue growth of 5.8% per year, both trailing respective US market averages. Investors are weighing a strong margin story and steady, if modest, long-term growth potential as they digest these...

American Riviera Bancorp (ARBV) posted net profit margins of 21.2%, a notable improvement from 19.8% a year ago. Annual earnings jumped 11%, outperforming its own five-year average rate of -0.3% per year. Despite this momentum, the longer-term trend remains flat, with five-year earnings dipping by an average of 0.3% each year. Against this backdrop, investors are likely to focus on both the encouraging uptick in profitability and the stock's potential undervaluation, balanced by lingering...

Northeast Community Bancorp (NECB) posted net profit margins of 42.7% this year, down from 45.9% last year. Annual revenue is forecast to grow at 7.8%, and EPS is projected to increase by 3.1% per year, both trailing the broader US market. Over the last five years, earnings growth averaged a robust 31.6% per year, but the most recent year saw a decline, setting a nuanced backdrop for investors. With the company trading at a Price-To-Earnings ratio of 5.6x, well below both industry and peer...

MoneyGram Haas F1 Team recently announced a new partnership with CSG Systems International, debuting their collaboration at the 2025 Formula 1 United States Grand Prix in Austin, Texas, to emphasize their shared commitment to innovation and performance. This partnership leverages the global exposure and fast-paced environment of Formula 1 racing to highlight CSG's expertise in empowering brands to engage customers and manage complexity. We'll now examine how CSG's new Formula 1 alliance...

Trying to decide what to do with First Merchants stock? You’re not alone; a lot of investors have been puzzling over whether this regional banking name is poised for a breakout or if the best gains are already behind it. Over the last year, First Merchants delivered an 8.0% gain, even after some recent choppiness. The stock is up 4.4% in the past week, but has slipped -2.5% over the last month and remains down -4.7% year-to-date. Longer-term holders, though, are still sitting on a hefty 69.7%...

If you’re watching Xeris Biopharma Holdings right now, you’re definitely not alone. It’s the sort of stock that sparks debate. Should you lock in gains, hold on for more, or steer clear as momentum cools? Over the past year, Xeris has delivered an eye-popping 187.8% return, and so far, 2024’s rally is even more dramatic with shares up 166.2% year-to-date. While last week’s dip of 0.3% barely raised eyebrows, the 12.6% jump over the last month has many investors paying close attention to every...

Arcturus Therapeutics Holdings (ARCT) drew intense investor attention after it released interim results from a Phase 2 trial for its cystic fibrosis treatment, ARCT-032. The report showed no substantial lung function improvement, which triggered sharp share declines and analyst downgrades. See our latest analysis for Arcturus Therapeutics Holdings. It has been a turbulent year for Arcturus Therapeutics. Shares have dropped sharply after underwhelming trial news and legal scrutiny, leading to...